Abstract
Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.
| Original language | English (US) |
|---|---|
| Article number | 57 |
| Journal | Translational Gastroenterology and Hepatology |
| Volume | 5 |
| DOIs | |
| State | Published - Oct 2020 |
Keywords
- Epithelial-mesenchymal transition (EMT)
- Gastric cancer (GC)
- Immunology
- Molecular biology
- Peritoneal carcinomatosis (PC)
- Peritoneal metastases
ASJC Scopus subject areas
- Hepatology
- Gastroenterology